Effect of monoclonal antibody-neocarzinostatin conjugate for gastric cancer with peritoneal dissemination--comparison between early and late administration
Okamoto, K.; Otsuji, E.; Toma, A.; Kobayashi, S.; Kitamura, K.; Yamaguchi, T.; Yamagishi, H.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(11): 1508-1510
2001
ISSN/ISBN: 0385-0684 PMID: 11707966 Document Number: 537317
A7-NCS, which is a conjugate of the monoclonal antibody A7 against a human colonic cancer and the anticancer agent neocarzinostatin (NCS), reacts with human gastric cancers at a high rate. The anticancer effect of A7-NCS is stronger than that of free NCS. Nude mice models of peritoneal dissemination were established simply by intra-peritoneal inoculation of the antigen-positive human gastric cancer cell line MKN45. Using these models, the anticancer effect of A7-NCS against the peritoneal dissemination of gastric cancer was examined. The murine peritoneal dissemination models were divided into three groups. The anticancer effect of the group injected intra-peritoneally with A7-NCS 2 days after cancer inoculation was compared with that injected 18 days after inoculation. The anticancer effect in the 18-day group was inferior to that in the 2-day group, but was superior to that in the non-treated group. To get a better result in the 18-day group, which is in the advanced stage of peritoneal dissemination, repeated injection and the dose of A7-NCS should be examined.